DAPERB 3,4-DiAminoPyridine and Electrophysiological Response in Brugada Syndrome
Status:
Terminated
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The Brugada syndrome is a rare disease potentially leading to severe arrhythmic events in
otherwise healthy subjects.In many patients an Implantable cardiovertor defibrillator (ICD)
is implanted to prevent sudden cardiac death. ICD are however associated with potential
complications and are not available in all countries.Pharmacological blockade of specific ion
channels (Ito) represents a promising therapeutic approach in this syndrome.The
3,4-diaminopyridine (3,4-DAP) is a pharmacological Ito blocker that can be used in humans.The
aim of the study is to evaluate the effect of 3,4-DAP on ventricular arrhythmia inducibility
in Brugada patients requiring an electrophysiological study for arrhythmic risk
stratification.